IOM Urges Data Sharing | The Scientist Magazine®
abernard102@gmail.com 2015-01-17
Summary:
"In recent years, advocates for consumers and transparency have been pushing regulatory agencies, journals, and clinical study sponsors to make human experimental data more accessible to independent scrutiny. In an attempt to balance the opposing forces of transparency and intellectual property, the Institute of Medicine (IOM) yesterday (January 14) laid out its guidance for when drug developers should share certain elements of clinical trials, including the protocol, summary results, and full dataset ..."